You are here

GATEWAY BIOTECHNOLOGY, INC.

Company Information
Address
6909 WASHINGTON AVE
SAINT LOUIS, MO 63130-4309
United States



Information

DUNS: 968854815

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Targeting multiple signaling pathways for tinnitus prevention and treatment

    Amount: $972,613.00

    Subjective tinnitus is the perception of a phantom sound, which negatively impacts the quality of life for millions of people worldwide. Despite the great demand for remedy, there are no FDA-approved ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Developing a Nutraceutical Product against Ototoxicity

    Amount: $205,183.00

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lu ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  3. An unique patient population for clinical trials against noise-induced hearing loss

    Amount: $324,572.00

    AbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrentl ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  4. Developing a new AAV-based tool for targeted gene therapy against hearing loss

    Amount: $224,700.00

    Project Summary Gene therapy mediated by recombinant adeno associated virusrAAVvectors has been clinically successful for the treatment of certain eye diseasesHoweverno successful clinical outcomes ex ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Develop a new cisplatin based drug combination with reduced ototoxicity

    Amount: $224,700.00

    PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side ef ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  6. Developing a Nutraceutical Product against Noise Induce Hearing Loss

    Amount: $224,700.00

    PROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  7. Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss

    Amount: $224,701.00

    DESCRIPTION provided by applicant Noise is the most common occupational and environmental hazard thus it is not surprising that noise induced hearing loss NIHL is the second most common form of ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  8. A new two-drug combination therapy for noise-induced hearing loss

    Amount: $224,700.00

    DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government